Nuvectis Pharma Inc.
NVCT | NASDAQ
$22.21
+$0.23 (+1.05%)
Sep 22, 2026, 9:30 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -5.72 | -4.87 | -5.83 | -4.97 | -2.98 | -4.06K |
PEG Ratio | -0.30 | 0.22 | 1.10 | -0.13 | 0 | n/a |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 8.94 | 9.53 | 10.63 | 6.68 | -3.75 | -4.13K |
P/FCF Ratio | -10.29 | -7.56 | -8.13 | -7 | -4.35 | n/a |
P/OCF Ratio | -10.29 | -7.56 | -8.13 | -7 | -4.35 | n/a |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Quick Ratio | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 | n/a |
Current Ratio | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 | n/a |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -143.61% | -195.61% | -182.44% | -134.22% | 117.10% | 100% |
Return on Assets | -83.39% | -102.11% | -116.03% | -93.53% | -193.63% | n/a |
Return on Invested Capital | -149.75% | -204.33% | -187.66% | -135.27% | -304.25% | 100% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove NVCT